SLNO · As filed with the SEC
Soleno Therapeutics cash flow statement, by fiscal year
The statement as Soleno Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Net income (loss) | 20,890,000 | (175,850,000) | (38,988,000) | (24,067,000) | (30,910,000) | (24,639,000) | (30,774,000) | (13,335,000) |
| Loss from discontinued operations | — | — | — | — | — | — | — | (1,494,000) |
| Loss from continuing operations | — | — | — | — | — | — | (30,774,000) | (11,841,000) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||||||||
| Depreciation and amortization | 2,017,000 | 1,987,000 | 1,958,000 | 1,964,000 | 1,963,000 | 1,954,000 | 1,958,000 | 1,963,000 |
| Accretion of premium/discount on marketable securities | (3,517,000) | (4,895,000) | — | — | — | — | — | — |
| Non-cash lease expense | 607,000 | 444,000 | 321,000 | 290,000 | 288,000 | 283,000 | 386,000 | — |
| Amortization of debt issuance costs | 35,000 | — | — | — | — | — | — | — |
| Stock-based compensation expense | 45,846,000 | 99,958,000 | 5,945,000 | 2,530,000 | 3,276,000 | 1,500,000 | 825,000 | 988,000 |
| Board fees paid with common stock | — | — | — | — | — | — | — | 275,000 |
| Change in fair value of stock warrants | 0 | 0 | 182,000 | (30,000) | (508,000) | (11,637,000) | 6,964,000 | (522,000) |
| Change in fair value of contingent consideration | 5,536,000 | 3,242,000 | 2,714,000 | (712,000) | (731,000) | 4,340,000 | 289,000 | 567,000 |
| Gain on deconsolidation of former subsidiary | — | — | — | — | — | — | — | (1,994,000) |
| Operating loss of minority interest investment | — | — | — | — | — | — | 478,000 | 160,000 |
| Other non-cash reconciling items | 17,000 | — | — | — | — | — | — | — |
| Change in operating assets and liabilities: | ||||||||
| Accounts receivable | (28,208,000) | — | — | — | — | — | — | — |
| Inventory | (14,031,000) | — | — | — | — | — | — | — |
| Prepaid expenses, other current assets and other assets | (4,738,000) | (750,000) | (837,000) | 113,000 | (139,000) | (549,000) | 10,000 | (60,000) |
| Due from related party | — | — | — | — | — | — | 64,000 | (64,000) |
| Accounts payable | 3,612,000 | 5,672,000 | 1,372,000 | (1,477,000) | (235,000) | 1,494,000 | 1,061,000 | 249,000 |
| Accrued compensation and other current liabilities | — | — | — | — | — | — | — | (43,000) |
| Accrued compensation | 4,901,000 | 1,641,000 | 1,460,000 | 947,000 | (277,000) | 722,000 | 9,000 | — |
| Accrued clinical trial site costs | — | (1,567,000) | 171,000 | (198,000) | (369,000) | 1,790,000 | 1,679,000 | — |
| Operating lease liabilities | — | (183,000) | (309,000) | (302,000) | (263,000) | (305,000) | (360,000) | — |
| Operating lease liabilities | (308,000) | — | — | — | — | — | — | — |
| Other liabilities | 14,139,000 | 1,205,000 | 1,071,000 | 161,000 | 135,000 | (177,000) | 36,000 | — |
| Net cash used in continuing operating activities | — | — | — | — | — | — | (17,375,000) | (10,322,000) |
| Net cash used in discontinued operating activities | — | — | — | — | — | — | — | (1,361,000) |
| Net cash provided by (used in) operating activities | 46,798,000 | (69,096,000) | (24,940,000) | (20,781,000) | (27,770,000) | (25,224,000) | (17,375,000) | (11,683,000) |
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | (73,000) | (218,000) | 0 | (13,000) | (22,000) | (7,000) | (21,000) | (8,000) |
| Security deposit on sublease | — | — | — | — | — | — | (59,000) | — |
| Security deposit received from expired lease | — | — | — | — | — | — | 108,000 | — |
| Proceeds from sale of minority interest investment in former subsidiary | — | — | — | — | — | — | 500,000 | — |
| Net cash provided by (used in) continuing investing activities | — | — | — | — | — | — | 528,000 | (8,000) |
| Net cash used in discontinued investing activities | — | — | — | — | — | — | — | (172,000) |
| Purchases of marketable securities | (455,776,000) | (356,464,000) | — | — | — | — | — | — |
| Maturities of marketable securities | 254,068,000 | 131,000,000 | — | — | — | — | — | — |
| Net cash used in investing activities | (201,781,000) | (225,682,000) | 0 | (13,000) | (22,000) | (7,000) | 528,000 | (180,000) |
| Cash flows from financing activities: | ||||||||
| Gross proceeds from sale of common stock and common stock warrants | — | — | — | 15,152,000 | — | 53,722,000 | 14,483,000 | — |
| Payment of issuance costs | — | — | — | (1,044,000) | — | — | — | — |
| Proceeds from sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs | — | — | 137,857,000 | — | — | — | — | — |
| Proceeds from exercise of common stock warrants and pre-funded stock warrants, net of costs | — | — | 41,815,000 | — | — | — | — | — |
| Proceeds from issuance of debt, net of issuance costs | 0 | 49,888,000 | — | — | — | — | — | — |
| Payment of debt issuance costs | (62,000) | — | — | — | — | — | — | — |
| Proceeds from the sale of common stock, net of issuance costs | 215,721,000 | 148,955,000 | — | — | — | — | — | — |
| Proceeds from sale of common stock and common stock warrants | — | — | — | — | — | — | — | 16,500,000 |
| Cash paid for the issuance of common stock and common stock warrants | — | — | — | — | — | — | — | (198,000) |
| Proceeds from the sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs | 0 | 0 | — | — | — | — | — | — |
| Payment for repurchase of common stock | 100,146,000 | — | — | — | — | — | — | — |
| Proceeds from exercise of common stock and pre-funded stock warrants | 5,187,000 | 12,866,000 | — | — | — | — | — | — |
| Proceeds from exercise of stock options | 17,202,000 | 1,316,000 | 347,000 | — | — | 17,000 | — | — |
| Tax withholding payments for net share-settled equity awards | (741,000) | 0 | 0 | (16,000) | (120,000) | — | — | — |
| Principal paid on finance lease liabilities | — | — | — | — | (8,000) | (17,000) | (2,000) | — |
| Net cash provided by continuing financing activities | — | — | — | — | — | — | 14,481,000 | 16,302,000 |
| Net cash provided by discontinued financing activities | — | — | — | — | — | — | — | 1,525,000 |
| Net cash provided by financing activities | 137,161,000 | 213,025,000 | 180,019,000 | 14,092,000 | (128,000) | 53,722,000 | 14,481,000 | 17,827,000 |
| Continuing Operations | — | — | — | — | — | — | (2,366,000) | 5,972,000 |
| Discontinued Operations | — | — | — | — | — | — | — | (8,000) |
| Net increase (decrease) in cash and cash equivalents | (17,822,000) | (81,753,000) | 155,079,000 | (6,702,000) | (27,920,000) | 28,491,000 | (2,366,000) | 5,964,000 |
| Cash and cash equivalents, beginning of period | 87,928,000 | 169,681,000 | 14,602,000 | 21,304,000 | 49,224,000 | 20,733,000 | 23,099,000 | 17,135,000 |
| Cash and cash equivalents, end of period | 70,106,000 | 87,928,000 | 169,681,000 | 14,602,000 | 21,304,000 | 49,224,000 | 20,733,000 | 23,099,000 |
| Supplemental disclosure of non-cash operating and financing information | ||||||||
| Accrued liability for cost of issuing common stock | — | — | — | — | — | — | — | 52,000 |
| Warrants issued in connection with sale of common stock | — | — | — | — | — | — | — | 582,000 |
| Operating lease right-of-use assets obtained in exchange for operating lease obligations | 0 | 2,835,000 | 597,000 | — | 581,000 | — | — | — |
| Cash paid for interest | 4,534,000 | — | — | — | — | — | — | — |
| Common stock repurchase costs included in accounts payable | 4,000 | — | — | — | — | — | — | — |
| Non-cash exercise of 2018 PIPE Warrants | 0 | 0 | 183,000 | — | — | — | — | — |
| Purchases of property and equipment included in accounts payable | 0 | 1,000 | — | — | — | 1,000 | — | — |
| Debt issuance costs included in accounts payable | 0 | 62,000 | — | — | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.